Editas Medicine
EDIT
222 hedge funds and large institutions have $481M invested in Editas Medicine in 2023 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 76 increasing their positions, 62 reducing their positions, and 39 closing their positions.
75% more call options, than puts
Call options by funds: $6.1M | Put options by funds: $3.5M
23% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 62
1% more capital inflows, than outflows
Capital inflows: $89.7M | Capital outflows: $89.2M
2.27% less ownership
Funds ownership: 77.04% → 74.77% (-2.3%)
7% less funds holding
Funds holding: 238 → 222 (-16)
36% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deep Track Capital
Greenwich,
Connecticut
|
+$31.3M |
| 2 |
BlackRock
New York
|
+$4.84M |
| 3 |
Woodline Partners
San Francisco,
California
|
+$4.38M |
| 4 |
Squarepoint
New York
|
+$4.18M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Avidity Partners Management
Dallas,
Texas
|
-$24.7M |
| 2 |
Ghisallo Capital Management
Boston,
Massachusetts
|
-$8.02M |
| 3 |
State Street
Boston,
Massachusetts
|
-$7.47M |
| 4 |
Man Group
London,
United Kingdom
|
-$6.35M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$5.52M |
EDIT Hedge Fund Activity: Q3 2023 in Review
222 of the 6,317 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q3 2023, worth a combined $481M — down 6.9% from $517M a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of EDIT and 25 opened new positions — a net loss of 14 holders — while 62 trimmed existing stakes and 76 added.
The largest buyer was Deep Track Capital, adding an estimated $31.3M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $24.7M sold.
- 222 institutional investors held Editas Medicine (EDIT) as of Q3 2023, down from 238 in Q2 2023.
- Funds reported $481M of Editas Medicine stock for Q3 2023, down 6.9% quarter-over-quarter.
- 25 funds opened new Editas Medicine positions in Q3 2023 and 39 closed out, a net change of -14 holders.
- The largest Editas Medicine buyer in Q3 2023 was Deep Track Capital, an estimated $31.3M added.
- The largest Editas Medicine seller in Q3 2023 was Avidity Partners Management, an estimated $24.7M sold.
Based on aggregated 13F filings for Q3 2023.